Xynomic Research Institute (XRI), a subsidiary of Xynomic Pharmaceuticals Holdings, has designed a series of potent RET kinase inhibitors by computer-assisted drug design, it was reported yesterday.
The company's cRET kinase inhibitors are a range of acetylene derivatives with novel and stable structures. Preliminary activity tests indicated that they showcased outstanding selectivity and inhibitory activity against TT tumour cells, and some compounds were identified as having submicromolar IC50 values in the mid- to low-nanomolar range. Further structure-activity relationship studies are presently underway to screen and receive lead compounds.
Y Mark Xu, chairman and CEO of Xynomic, said, 'XRI focuses on research and development of innovative oncology drug candidates. We have recently upgraded our infrastructure and equipment and hired additional scientists. We believe that we are now well positioned to fully leverage XRI's capacity to efficiently design and synthesise cutting edge molecules.'
XRI has already filed global patents for internally discovered pre-clinical drug candidates XP-103 and XP-104.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients